Rare and Atypical Diabetes Network
RADIANT
3 other identifiers
observational
2,000
1 country
13
Brief Summary
RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to:
- 1.Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes.
- 2.Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes.
- 3.Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2020
Longer than P75 for all trials
13 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 30, 2020
CompletedFirst Submitted
Initial submission to the registry
August 23, 2022
CompletedFirst Posted
Study publicly available on registry
September 16, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 1, 2030
August 14, 2025
August 1, 2025
9.9 years
August 23, 2022
August 11, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Phenotypic and genotypic characterization of previously unknown forms of diabetes using Whole Genome Sequencing (WGS), and deeper phenotyping methods
Deeper phenotyping methods include both clinical and laboratory assessments. Clinical data includes anthropometric and biometric data, medical histories, and standard questionnaires (ASA24, PROMIS, environmental exposures depression and anxiety). Laboratory data includes WGS, transcriptomics, metabolomics, mitochondrial sequencing, Oral Glucose Tolerance Test (OGTT), and Islet autoantibodies. Clustering methods will be used to define cohorts of similar diabetes genotypes and phenotypes based on this data.
Through study completion, an average of 3 years.
Eligibility Criteria
Probands and family members will be screened for evaluation of suspected atypical diabetes of unknown origin. Among the pool of evaluated individuals, those found to have a known form of diabetes will be excluded from further study. The remaining participants will be prioritized for genetic/genomic analysis and further testing.
You may qualify if:
- The following criteria or phenotypes will be considered for suspecting "atypical" participants:
- Type 2 diabetes diagnosed at a time when the individual was prepubertal or non-obese
- Mendelian pattern, especially with early onset (\<18 years old)
- Syndromic (multiple systems involved)
- Lipodystrophic
- Extremes of BMI
- "Mitochondrial" characteristics (e.g., myopathy, hearing deficits)
- Non-progressive
- Rapidly progressive ("fulminant")
- Low insulin requirements (\<0.5 u/kg/day)
- Cyclical hyperglycemia with periods of remission
- Lean persons with polycystic ovarian syndrome (PCOS)
- History of gestational diabetes (GDM) when lean
- Lean insulin-resistant persons
- If islet autoantibodies and beta-cell function parameters have been measured (where "A" = islet cell autoantibodies, "B" = beta-cell function):
- +1 more criteria
You may not qualify if:
- Those with high likelihood of typical type 1, typical type 2, known monogenic, or other known secondary forms of diabetes
- Refusal of consent for genetic testing
- Islet autoantibody positive (participants who are islet autoantibody positive but present with additional atypical features i.e. syndromic, strong linear family history of diabetes may not be excluded)
- Women who are currently pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (13)
University of Colorado- Denver
Aurora, Colorado, 80045, United States
University of Chicago
Chicago, Illinois, 60637, United States
Indiana University
Indianapolis, Indiana, 46202, United States
University of Maryland
Baltimore, Maryland, 21201, United States
Massachusetts General Hospital (MGH)
Boston, Massachusetts, 02114, United States
University of Michigan
Ann Arbor, Michigan, 48109, United States
Washington University in St. Louis
St Louis, Missouri, 63110, United States
SUNY Downstate Health Sciences University
Brooklyn, New York, 11203, United States
Columbia University
New York, New York, 10032, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
Vanderbilt University
Nashville, Tennessee, 37232, United States
Baylor College of Medicine
Houston, Texas, 77030, United States
University of Washington
Seattle, Washington, 98109, United States
Related Publications (1)
RADIANT Study Group. The Rare and Atypical Diabetes Network (RADIANT) Study: Design and Early Results. Diabetes Care. 2023 Jun 1;46(6):1265-1270. doi: 10.2337/dc22-2440.
PMID: 37104866DERIVED
Biospecimen
Whole Blood Serum Plasma DNA RNA Urine Peripheral Blood Monocytes (PBMCs)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Jeffrey Krischer, PhD
University of South Florida
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 23, 2022
First Posted
September 16, 2022
Study Start
September 30, 2020
Primary Completion (Estimated)
September 1, 2030
Study Completion (Estimated)
September 1, 2030
Last Updated
August 14, 2025
Record last verified: 2025-08